INFORMATION ABOUT THE TABLET FORM OF EVRYSDI DRUG WITH RISDIPLAM ACTIVE INGREDIENT

FDA approved the tablet form of Evrysdi drug with the active ingredient Risdiplam!

CureSMA shared the information on the subject; Genentech, a member of the Roche group, is a member of the US Food and Drug Administration. FDA's Evrysdi® He stated that he shared with the public that the application for the new tablet form of (risdiplam) treatment was approved. ????

This approval for Evrysdi in tablet form is based on the results of the bioequivalence study and also states that the 5 mg tablet should be swallowed whole or in chlorine-free drinking water (filtered water). etc.) When dissolved, it was stated that it had similar effects to the original oral solution.

In the information given by CureSMA; It has been stated that the new tablet is expected to be launched in the coming weeks.
Finally; It has been stated that it will be suitable for individuals weighing 20 kg and above, and for individuals aged 2 years and above. href="https://www.curesma.org/fda-approves-genentechs-evrysdi-tablet-as-first-and-only-tablet-for-spinal-muscular-atrophy-sma/">you can access the shared information here. You can follow the developments in the processes through our foundation's social media channels and our website.